Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982534 | 0.88 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL31319696 | 0.83 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL1012600 | 0.83 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL1256324 | 0.83 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL8765236 | 0.79 | — | — | |
| SCHEMBL586720 | 0.79 | CA2 (0.35) | — | |
| SCHEMBL12650126 | 0.78 | HCAR2 (0.35) | MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL2943006 | 0.77 | MEN1 (0.46) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3712259 | 0.77 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL23966693 | 0.76 | ALDH1A1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-05 | — | — | US | disclosed |
| EP-4430042-B1 | 6-HETERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| EP-4313293-B1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-05-07 | — | — | EP | disclosed |
| EP-4240738-B1 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | LILLY CO ELI (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4313994-B1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-05 | — | — | EP | disclosed |
| EP-4506349-A2 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-02-12 | — | — | EP | disclosed |
| US-20240391936-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-11-28 | — | — | US | disclosed |
| EP-3904355-B1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| EP-4430042-A1 | 6-HE TERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2014141187-A1 | PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014141187-A1 | PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391936-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | MEN1 3642/4885KMT2A 3309/4885KIT 1939/4885 |
| US-12617801-B2 | Tetrahydrothieno pyridine derivatives as DDRS inhibitors | DDR1, DDR2, DDRGK1 | MEN1 3539/4885KMT2A 3599/4885KIT 3486/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MEN1 3221/4885KMT2A 2544/4885KIT 2220/4885 |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | MEN1 1373/4885KMT2A 293/4885KIT 4/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MEN1 2033/4885KMT2A 1484/4885KIT 2062/4885 |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | BRAF, ALK, TYRO3 | MEN1 2285/4885KMT2A 1820/4885KIT 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.